Minerva Neurosciences, Inc.
- NERV
- NASDAQ
- Biotechnology
- CNS/Neurological Therapeutics
- Clinical-Stage Biopharma
$2.44
Today +5.17%Quote Oct 20, 2026, 02:06 PM UTC
−36.61%over the last month
Max drawdown −39.1%From 1-month high −39.1%3 months −48.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Minerva Neurosciences
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
7
Market value
$116.5M
Quote Oct 20
Analyst target
$10.00
+309.8% from here
Floor
$2.42
0.7% below price
Resistance
$2.57
5.5% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about NERVPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free